Slide 1: Q1 2026 Financial Results
Q1 2026 Financial Results April 28, 2026 Nasdaq: NEO
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-
Slide 3: Mission and Vision
Mission We save lives by improving patient care. Vision We are becoming the world’s leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services.
Slide 4: NEO: Investment Thesis
NEO: Investment Thesis 04 A “pure play” oncology solutions provider Entering the rapidly-growing $20+ billion solid 01 driving rapid dissemination and adoption of 04 tumor MRD (minimum residual disease) cancer monitoring market with the launch of RaDaR ST innovation through its best-in-class commerc
Slide 5: One Provider from Diagnosis to Recurrence Monitoring
One Provider from Diagnosis to Recurrence Monitoring MRD Diagnostic Testing Therapy Selection Recurrence Monitoring $12B | 7% CAGR $13B | 13-15% CAGR $20B | 30% CAGR Penetration: 70% 35% <8% Flagship products: Sources: SEER, NCCN, NHS, NSF, NIH, UN, WHO, Precedence Research, primary market research,
Slide 6: Strong Revenue and Adj EBITDA Growth
Strong Revenue and Adj EBITDA Growth Revenue ($M) Adj EBITDA ($M) $187M $9M $168M $7M 11% 27% YoY YoY growth growth Q1 2025 Q1 2026 Q1 2025 Q1 2026 Quarterly financial information is unaudited. Growth corresponds to prior year period. Adjusted EBITDA is a non-GAAP financial measure. See Adjusted EBI
Slide 7: Clinical Performance Drives Growth
Clinical Performance Drives Growth Clinical Revenue Revenue per Test Volume (tests) 361k $174M $495 357k $172M $171M $488 356k 346k $164M $476 $461 $150M $459 326k 14% Reported 8% Reported 6% Reported 12% Same Store 9% Same Store 3% Same Store Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 2025 2025 2
Slide 8: NGS is the Performance Catalyst
NGS is the Performance Catalyst +26% NGS Revenue +16% NGS Volume NGS Revenue Low-mid Twenties YoY Revenue Growth Mid-teens YoY Volume Growth ~1/3 of Clinical Revenue 26% 16% NGS Volume ~10% of Clinical Volume in Q1 CGP Panels Driving outsized revenue growth Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 2025 2025 20
Slide 9: NGS Growth Scaling ~3-4x Faster than Core Clinical
NGS Growth Scaling ~3-4x Faster than Core Clinical $171M $659M $571M $150M NGS +26% ~1/3 $496M ~1/5$419M Core +9% ~1/5 Same Store +6% 2022 2023 2024 2025 Q1 Q1 2025 2026 NGS Revenue Core Clinical Revenue Quarterly financial information is unaudited. Growth corresponds to prior year period.
Slide 10: Winning in the Community Setting
Winning in the Community Setting It’s where approximately 80% of cancer patients receive their care Guideline Leading Hematology Geographically Comprehensive Oncology- Driven Market Share Diverse Lab Network Focused Test Menu Community oncologists select >25% heme market share Delivering some of the
Slide 11: Launched RaDaR ST for MRD in Feb'26
Launched RaDaR® ST for MRD in Feb’26 Tapping into the large, nascent, & rapidly growing cancer recurrence monitoring market RaDaR ST Early Insights4 New MolDx reimbursement Indication Prevalence1 secured2 Diagnosis1 • Strong Customer Re-engagement: 29% return users from RaDaR 1.0 Head and neck 20K 6
Slide 12: Expanding the PanTracer Portfolio with Pro
Expanding the PanTracer Portfolio with Pro Eliminating order complexity, PanTracer Pro delivers the right tests at the right time, and enables therapy decision-making with timely, relevant results to improve patient outcomes. Actionable information Reduces delays in Optimized workflow Includes over
Slide 13: PanTracer Pro Ovarian Example
PanTracer Pro Ovarian Example Comprehensive, Actionable Results in One Order IHC Report Sent NGS Report Sent Physician Accessioning Orders Receives PanTracer Pro Sample + Order Day 0 Day 4 Day 8 Path Report Review Dx = Ovarian Cancer Oncotree Test Add-Ons • FOLR1 PD-L1 22C3 FDA for Ovarian Carcinoma
Slide 14: Sales Force Expansion Driving Accelerated Penetration
Sales Force Expansion Driving Accelerated Penetration ~75% of community oncologists new to NEO in 2025 ordered 5+ tests NEO Community Oncologist NPI and Sales Headcount Trends, 2023-2025 Demonstrated ability of taking market share 9,000*+ even with later product introductions due to our 8,000+ stren
Slide 15: Gross Margin Expected to Increase by 100 bps
Gross Margin Expected to Increase by 100 bps In 2026 Adj Gross Profit & Margin $88M +100 bps $86M $85M $82M Adj Gross Profit: + 9% YoY Adj Gross Margin: -80 bps $79M 47% 45% 45% 46% 46% 46% 47% Q1 Q2 Q3 Q4 Q1 FY FY 2026 2025 2025 2025 2025 2026 2025 Est • Pathline acquisition and Pan Tracer LBx drov
Slide 16: Operating Expense, Margin and Cash Position
Operating Expense, Margin and Cash Position OPERATING EXPENSE ADJ. EBITDA ADJ. EBITDA MARGIN TOTAL CASH $99M $9M 4.8% $146M (2%) YoY +27% YoY +60 bps YoY Period-end balance Operating Leverage Cash Position • OpEx down (2%) YoY to $99M, primarily driven by non • Cash used in operations of $8M in Q1 2
Slide 17: Full Year 2026 Guidance
Full Year 2026 Guidance Guidance as of April 28th, 2026 Guidance as of February 17th, 2026 ($ Millions) YoY% Growth Assumptions Guide ($ Millions) YoY% Growth • Continued momentum in NGS • RaDaR revenue in MSD millions Revenue $793 - $801 ~10% $797 - $803 10% • PanTracer LBx Revenue in MSD at midpoi
Slide 18: Growth Catalysts 2026+
Growth Catalysts 2026+ 1 RaDaR ST launch for HPV- Head & Neck, subset of Breast 2 PanTracer LBx MolDx reimbursement 3 Expanded indication reimbursement for RaDaR ST 4 Above market NGS growth 5 Sales force expansion
Slide 19: Business Levers for Accelerated Financial Performance
Business Levers for Accelerated Financial Performance Product Commercial Execution Operations • RaDaR ST adoption in • Sales force expansion • Digital pathology Lab of the Future Head and Neck, Breast • Automation & AI • Pricing and Revenue Cycle • RaDaR ST indication Management initiatives • Instru
Slide 20: All rights reserved
© 2026 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. 02.17.2026
Slide 21: Appendix
GENOMICS Appendix
Slide 22: Balance Sheet
March 31, 2026 (unaudited) December 31, 2025 ASSETS Current assets Balance Cash and cash equivalents $ 146,143 $ 159,618 Accounts receivable, net 167,424 159,242 Inventories 29,837 28,566 Sheet Prepaid assets Other current assets 23,666 6,614 21,443 7,417 March 31, 2026 Total current assets Property
Slide 23: Income Statement
Three Months Ended March 31, 2026 2025 Income NET REVENUE $ 186,672 $ 168,035 COST OF REVENUE 105,808 94,789 Statement GROSS PROFIT 80,864 73,246 March 31, 2026 Operating expenses: General and administrative 65,741 68,207 (unaudited, in thousands) Research and development 9,534 10,181 Sales and mark
Slide 24: Statements of Cash Flows
Three Months Ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES Statements of Net loss Adjustments to reconcile net loss to net cash used in operating activities: $ (17,106) $ (25,923) Cash Flows Depreciation 8,780 9,366 Amortization of intangibles 7,633 8,362 Stock-based compensation 9,
Slide 25: Adjusted Gross Margin
Three Months Ended March 31, 2026 2025 % Change Adjusted Consolidated: Total revenue (GAAP) $ 186,672 $ 168,035 11.1 % Gross Margin Cost of revenue (GAAP) $ 105,808 $ 94,789 11.6 % March 31, 2026 Adjustments to cost of revenue(1) Adjusted cost of revenue (non-GAAP) (4,951) $ 100,857 (5,325) $ 89,464
Slide 26: Adjusted EBITDA
Three Months Ended March 31, 2026 2025 Adjusted Net loss (GAAP) $ (17,106) $ (25,923) Adjustments to net loss: Interest income (1,273) (3,721) EBITDA Interest expense Income tax (benefit) expense 598 (472) 1,618 266 March 31, 2026 Depreciation 8,780 9,366 Amortization of intangibles 7,633 8,362 (una
Slide 27: 2026 Guidance Adjusted EBITDA
Year Ended December 31, 2026 Low Range High Range Net loss (GAAP) $ (63,000) $ (50,000) Amortization of intangibles 30,000 30,000 Adjusted Stock-based compensation expenses Other one-time expenses Adjusted net income (non-GAAP) 43,000 11,000 21,000 40,000 7,000 27,000 EBITDA Interest and taxes Depre